Amyndas reports Phase I data for C3 inhibitor AMY-101

Amyndas Pharmaceuticals S.A. (Glyfada, Greece) reported data from an open-label, U.S. Phase I trial in healthy male volunteers showing that single and multiple ascending doses of subcutaneous and IV AMY-101 achieved a "very good safety profile." Additionally, the company said pharmacokinetic data support subcutaneous dosing of the compstatin-derived complement 3 (C3) inhibitor every 48 hours...